• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Drug Products
  • All Drug Products

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • expand A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy.
    Study Id
    D7913L00138
    Disease
    lung cancer
    Drug Name
    IRESSA
    Study Name
    Icarus
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)
    Study Id
    D5130L00014
    Disease
    acute coronary syndrome
    Drug Name
    Brilinta
    Study Name
    D5130L00014
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections
    Study Id
    D3720C00001
    Disease
    infectious diseases, skin and soft tissue infection
    Study Name
    D3720C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
    Study Id
    D2850C00001
    Disease
    Cancer and Infection Research Area
    Study Name
    D2850C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry
    Study Id
    NIS-CDE-XXX-2011/1
    Disease
    acute coronary syndrome
    Drug Name
    non drug study (cardiovascular)
    Study Name
    NIS-CDE-XXX-2011/1
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I Open-Label Study to Assess the Safety and Tolerability of AZD2281(KU-0059436) in Combination with carboplatin (phase I), or in combination with a carboplatin/paclitaxel doublet (phase IIa), or in combination with paclitaxel (phase IIb) in the Treatment of Patients with Advanced Solid Tumours.
    Study Id
    D0810C00004
    Disease
    solid tumour
    Drug Name
    Olaparib
    Study Name
    KU36-96
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
    Study Id
    D1532C00067
    Disease
    non-small cell lung cancer
    Drug Name
    AstraZeneca Oncology and Infection Development Drugs
    Study Name
    D1532C00067
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Study to derive normative distribution of CIMT and to determine its cOrrelation with cardiovascular Risk factors in asymptomatic nationwidE Indian population. (SCORE India)
    Study Id
    NIS-CIN-XXX-2011/2
    Disease
    cardiovascular diseases
    Study Name
    NIS-CIN-XXX-2011/2
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease
    lymphoma
    Drug Name
    AstraZeneca Oncology and Infection Development Drugs
    Study Name
    D4302C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers
    Study Id
    D4280C00009
    Disease
    drug safety, pharmacokinetics
    Drug Name
    CAZ-104
    Study Name
    D4280C00009
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013